Quaker Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quaker Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229	Sell	4 -4	-50%	-$219	﹤0.01%	868
2026 Q1	$452	Buy	8 +6	+300%	+$350	﹤0.01%	718
2025 Q4	$119	Buy	+2	New	+$109	﹤0.01%	916

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quaker Wealth Management's BMRN Position: Q2 2026 in Review

Quaker Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q2 2026, selling an estimated $219 and leaving 4 shares worth $229. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Quaker Wealth Management first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $452 in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Quaker Wealth Management held 4 shares of BioMarin Pharmaceuticals worth $229 as of Q2 2026.
Quaker Wealth Management sold 4 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $219.
BioMarin Pharmaceuticals made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #868 holding.
Quaker Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
Quaker Wealth Management's BioMarin Pharmaceuticals position peaked at $452 in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.